financetom
Business
financetom
/
Business
/
Stock Yards Bancorp's Q3 profit rises on higher interest income
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Stock Yards Bancorp's Q3 profit rises on higher interest income
Oct 29, 2025 4:59 AM

Overview

* Stock Yards Bancorp ( SYBT ) Q3 net income rises to $36.2 mln, driven by loan and deposit growth

* Net interest income increased 19% yr/yr, supported by asset growth and yield expansion

* Company's deposits grew 14% over the past 12 months, shifting to higher-cost deposits

Outlook

* Company expects net interest margin to remain stable despite potential rate cuts

* Stock Yards Bancorp ( SYBT ) plans to open two new locations by year-end

* Company sees growth in Wealth Management & Trust segment driven by strategic hires

Result Drivers

* LOAN GROWTH - Strong loan production across all markets contributed to record earnings, despite elevated loan payoffs, per CEO James A. Hillebrand

* DEPOSIT EXPANSION - Deposit base grew by $918 mln, driven by time deposit initiative and increased non-interest bearing deposits

* NON-INTEREST INCOME - Growth in mortgage and brokerage businesses supported non-interest income, despite a decline in WM&T income

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS $1.23

Q3 Net $36.24

Income mln

Q3 Net $77.03

Interest mln

Income

Q3 $1.97

Credit mln

Loss

Provisio

n

Q3 $0.32

Dividend

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the banks peer group is "buy."

* Wall Street's median 12-month price target for Stock Yards Bancorp Inc ( SYBT ) is $82.00, about 18.1% above its October 28 closing price of $67.12

* The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 18 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Western Midstream Says Occidental Affiliates Launch Secondary Unit Offering; Shares Fall After Hours
Western Midstream Says Occidental Affiliates Launch Secondary Unit Offering; Shares Fall After Hours
Aug 12, 2024
05:10 PM EDT, 08/12/2024 (MT Newswires) -- Western Midstream Partners ( WES ) said late Monday that Occidental (OXY) affiliates have launched a secondary public offering of 19 million Western Midstream ( WES ) common units representing limited partner interests in the company. The selling unit holders plan to grant a 30-day overallotment option to the underwriter to acquire up...
Invesco Assets Under Management Rise 0.9% in July
Invesco Assets Under Management Rise 0.9% in July
Aug 12, 2024
05:09 PM EDT, 08/12/2024 (MT Newswires) -- Invesco ( IVZ ) reported late Monday that its preliminary assets under management rose 0.9% month-on-month to $1.732 trillion at the end of July. The company said favorable market returns increased AUM by $9 billion, while foreign exchange increased AUM by $4.9 billion. ...
Sun Life quarterly profit rises on strong growth in Canada and Asian region
Sun Life quarterly profit rises on strong growth in Canada and Asian region
Aug 12, 2024
Aug 12 (Reuters) - Sun Life Financial ( SLF ), Canada's second-biggest life insurer, reported an 8.7% rise in second-quarter profit on Monday, boosted by strong growth at home and in the Asian region. The company's underlying net income was C$1 billion ($727.59 million) in the three months ended June 30, or C$1.72 per share, compared to C$920 million, or...
Syros Pharmaceuticals Ends Trial of Prospective Acute Myeloid Leukemia Treatment -- Shares Plunge
Syros Pharmaceuticals Ends Trial of Prospective Acute Myeloid Leukemia Treatment -- Shares Plunge
Aug 12, 2024
05:10 PM EDT, 08/12/2024 (MT Newswires) -- Syros Pharmaceuticals ( SYRS ) was plunging 67% in Monday after-hours session after saying it will stop enrolling new patients for a phase 2 trial of tamibarotene for acute myeloid leukemia with RARA gene overexpression after an interim analysis suggested the probability for success was low. The trial was studying tamibarotene with a...
Copyright 2023-2026 - www.financetom.com All Rights Reserved